Literature DB >> 34116834

The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients.

Carlo Ronsini1, Luigi Pedone Anchora2, Stefano Restaino3, Camilla Fedele1, Damiano Arciuolo4, Elena Teodorico2, Nicolò Bizzarri2, Gian Franco Zannoni5, Gabriella Ferrandina1, Giovanni Scambia6, Francesco Fanfani1.   

Abstract

OBJECTIVE: Lymph vascular space involvement (LVSI) is one of the most important prognostic factors in early stage cervical cancer. Its qualitative evaluation represents a milestone for patient risk stratification and treatment choice, but a semi-quantitative analysis of LVSI may offer a more truthful risk model, as already demonstrated for endometrial cancer. The present study aims to investigate the performances of a semi-quantitative evaluation of LVSI in terms of patient risk assessment.
METHODS: In this retrospective study were enrolled patients underwent surgical treatment for early cervical cancer from January 2009 to October 2018. A semi-quantitative evaluation such as the "three-tiered approach" was used to classify the LVSI pathway: negative vs. focal vs. diffuse.
RESULTS: Diffuse LVSI was found to be a risk factor for lymph node metastasis (OR: 9.844, p < 0.001), and parametrial involvement (OR: 5.566, p < 0.001). Lymph nodal recurrences were more frequent in diffuse LVSI group (LVSI negative vs. focal LVSI p = 0.369; LVSI negative vs. diffuse LVSI p = 0.002; Focal LVSI vs. diffuse LVSI p = 0.214); and so distant recurrences (LVSI negative vs. focal LVSI p = 0.623; LVSI negative vs. diffuse LVSI p = 0.002; Focal LVSI vs. diffuse LVSI p = 0.026). Patients with diffuse LVSI showed a worse disease-free survival (DFS) than patients with focal or absent involvement (DFS LVSI negative vs. focal LVSI p = 0.938; LVSI negative vs. diffuse LVSI p < 0.001; focal LVSI vs. diffuse LVSI p = 0.036).
CONCLUSION: Semi-quantitative evaluation of LVSI may be useful to identify risk patients for shorter disease-free survival and lymphatic and distant recurrences in patients with early stage.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Early stage cervical cancer; LVSI

Mesh:

Year:  2021        PMID: 34116834     DOI: 10.1016/j.ygyno.2021.06.002

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

Review 1.  Fertility-Sparing Treatment for Early-Stage Cervical Cancer ≥ 2 cm: A Problem with a Thousand Nuances-A Systematic Review of Oncological Outcomes.

Authors:  Carlo Ronsini; Maria Cristina Solazzo; Nicolò Bizzarri; Domenico Ambrosio; Marco La Verde; Marco Torella; Raffaela Maria Carotenuto; Luigi Cobellis; Nicola Colacurci; Pasquale De Franciscis
Journal:  Ann Surg Oncol       Date:  2022-09-05       Impact factor: 4.339

2.  Nomograms Predicting Survival of Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy Based on the 2018 FIGO Staging System.

Authors:  Qingyu Meng; Weiping Wang; Xiaoliang Liu; Dunhuang Wang; Fuquan Zhang
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

3.  The Effect of Surgeon Volume on the Outcome of Laser Vaporization: A Single-Center Retrospective Study.

Authors:  Michihide Maeda; Tsuyoshi Hisa; Shinya Matsuzaki; Misooja Lee; Seiji Mabuchi; Shoji Kamiura
Journal:  Curr Oncol       Date:  2022-05-23       Impact factor: 3.109

4.  The diagnostic value of core needle biopsy in cervical cancer: A retrospective analysis.

Authors:  Massimiliano Lia; Lars-Christian Horn; Paulina Sodeikat; Michael Höckel; Bahriye Aktas; Benjamin Wolf
Journal:  PLoS One       Date:  2022-01-05       Impact factor: 3.240

Review 5.  Neoadjuvant Chemotherapy Prior Fertility-Sparing Surgery in Women with FIGO 2018 Stage IB2 Cervical Cancer: A Systematic Review.

Authors:  Alessandro Buda; Martina Borghese; Andrea Puppo; Stefania Perotto; Antonia Novelli; Chiara Borghi; Elena Olearo; Elisa Tripodi; Alessandra Surace; Enrica Bar; Giovanni Scambia; Francesco Fanfani
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.